<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" version="2.0">
  <channel>
    <title>Mail.com: MERCK KGAA</title>
    <link>http://www.mail.com/in-en/companies/25066-merck-kgaa.html</link>
    <description>Mail.com - the best personalized free web-based Email</description>
    <language>en</language>
    <dc:language>en</dc:language>
    <image>
      <title>Mail.com: MERCK KGAA</title>
      <url>http://sec-s.uicdn.com/mail.com/2.29/img/mailcom_logo_rss.png</url>
      <link>http://www.mail.com/in-en/companies/25066-merck-kgaa.html</link>
    </image>
    <item>
      <title>Higher prices for MS drug help drug firm Merck</title>
      <link>http://www.mail.com/in-en/scitech/health/2083806-higher-prices-ms-drug-help-drug-firm-merck.html</link>
      <description>FRANKFURT, Germany (AP) — Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit. 
                   Merck also saw stronger sales of materials for liquid-crystal displays and raised its profit forecast, saying it would achieve its 2014 goals this year. Its op...</description>
      <pubDate>Tue, 14 May 2013 09:47:51 GMT</pubDate>
      <guid isPermaLink="false">http://www.mail.com/in-en/scitech/health/2083806-higher-prices-ms-drug-help-drug-firm-merck.html</guid>
      <dc:date>2013-05-14T09:47:51Z</dc:date>
    </item>
    <item>
      <title>Merck Q4 net profit more than doubles</title>
      <link>http://www.mail.com/in-en/business/economy/1937364-merck-q4-net-profit-than-doubles.html</link>
      <description>FRANKFURT, Germany (AP) — Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring. 
                   The Darmstadt-based company said Thursday that its net profit rose to €272 million ($355 million), from €133 mi...</description>
      <pubDate>Thu, 07 Mar 2013 08:17:13 GMT</pubDate>
      <guid isPermaLink="false">http://www.mail.com/in-en/business/economy/1937364-merck-q4-net-profit-than-doubles.html</guid>
      <dc:date>2013-03-07T08:17:13Z</dc:date>
    </item>
    <item>
      <title>Germany's Merck suffers setback with cancer drug</title>
      <link>http://www.mail.com/in-en/scitech/health/1776018-germanys-merck-suffers-setback-with-cancer-drug.html</link>
      <description>BERLIN (AP) — German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations. 
                   The company, based in Darmstadt, says the drug Stimuvax did not improve the overall survival of patients in the phase III study. Merck shares fell 3.1 percent to €98.20 ($129.41) after the announcement early Wednesday. ...</description>
      <pubDate>Wed, 19 Dec 2012 10:35:00 GMT</pubDate>
      <guid isPermaLink="false">http://www.mail.com/in-en/scitech/health/1776018-germanys-merck-suffers-setback-with-cancer-drug.html</guid>
      <dc:date>2012-12-19T10:35:00Z</dc:date>
    </item>
  </channel>
</rss>

